What was the market valuation of the US eye allergy-treatment market in 2024?

The market valuation was $745.5 Million in 2024. Read More

What is the projected market valuation for the US eye allergy-treatment market by 2035?

The projected valuation for 2035 is $1419.2 Million. Read More

What is the expected CAGR for the US eye allergy-treatment market during the forecast period 2025 - 2035?

The expected CAGR is 6.03% during the forecast period 2025 - 2035. Read More

Which drug class generated the highest revenue in the US eye allergy-treatment market?

Antihistamines generated between $200.0 Million and $400.0 Million in revenue. Read More

What are the revenue ranges for Seasonal and Perennial Allergic Conjunctivitis in the market?

The revenue range for Seasonal and Perennial Allergic Conjunctivitis is $300.0 Million to $600.0 Million. Read More

Which distribution channel is expected to have the highest revenue in the US eye allergy-treatment market?

Retail pharmacies are expected to generate between $372.7 Million and $709.2 Million. Read More

What treatment form is projected to have the highest revenue in the US eye allergy-treatment market?

Eyedrops are projected to generate between $300.0 Million and $600.0 Million. Read More

Who are the key players in the US eye allergy-treatment market?

Key players include Allergan, Novartis, Bausch Health, Regeneron Pharmaceuticals, and others. Read More

What is the revenue range for Atopic Keratoconjunctivitis in the market?

The revenue range for Atopic Keratoconjunctivitis is $80.0 Million to $150.0 Million. Read More

What revenue range is expected for Immunotherapy Allergy Shots in the US eye allergy-treatment market?

Immunotherapy Allergy Shots are expected to generate between $50.0 Million and $100.0 Million. Read More

US Eye Allergy Treatment Market

US Eye Allergy Treatment Market Research Report: By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules) and By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.03%

2024 Market Size

$ 745.5 Million

2035 Market Size

$ 1,419.2 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/11782-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Seasonal and Perennial Allergic Conjunctivitis
  2. 4.1.2 Vernal Keratoconjunctivitis
  3. 4.1.3 Atopic Keratoconjunctivitis
  4. 4.1.4 Contact Allergic Conjunctivitis
  5. 4.1.5 Giant Papillary Conjunctivitis
2. 4.2 Construction, BY Drug Class (USD Million)
  1. 4.2.1 Antihistamine
  2. 4.2.2 Mast Cell Stabilizer
  3. 4.2.3 NSAIDs
  4. 4.2.4 Corticosteroid
  5. 4.2.5 Decongestants
  6. 4.2.6 Immunotherapy Allergy Shots
  7. 4.2.7 Others
3. 4.3 Construction, BY Treatment Form (USD Million)
  1. 4.3.1 Eyedrops
  2. 4.3.2 Injectables
  3. 4.3.3 Tablets & Capsules
4. 4.4 Construction, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacy
  2. 4.4.2 Online Pharmacy
  3. 4.4.3 Retail Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bausch Health (CA)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Regeneron Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Santen Pharmaceutical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Horizon Therapeutics (IE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Aerie Pharmaceuticals (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ocular Therapeutix (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 US MARKET ANALYSIS BY TREATMENT FORM
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY DRUG CLASS, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY TREATMENT FORM, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY TREATMENT FORM, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT FORM, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Eye Allergy Treatment Market Segmentation

US Eye Allergy Treatment Market By Type (USD Million, 2025-2035)

Seasonal and Perennial Allergic Conjunctivitis
Vernal Keratoconjunctivitis
Atopic Keratoconjunctivitis
Contact Allergic Conjunctivitis
Giant Papillary Conjunctivitis

US Eye Allergy Treatment Market By Drug Class (USD Million, 2025-2035)

Antihistamine
Mast Cell Stabilizer
NSAIDs
Corticosteroid
Decongestants
Immunotherapy Allergy Shots
Others

US Eye Allergy Treatment Market By Treatment Form (USD Million, 2025-2035)

Eyedrops
Injectables
Tablets & Capsules

US Eye Allergy Treatment Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”